Immix Biopharma, Inc. (NASDAQ:IMMX - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2026 EPS estimates for Immix Biopharma in a note issued to investors on Wednesday, June 4th. HC Wainwright analyst R. Burns expects that the company will post earnings of ($0.14) per share for the quarter. HC Wainwright has a "Buy" rating and a $7.00 price target on the stock. The consensus estimate for Immix Biopharma's current full-year earnings is ($0.87) per share. HC Wainwright also issued estimates for Immix Biopharma's Q2 2026 earnings at ($0.15) EPS, Q3 2026 earnings at ($0.17) EPS, Q4 2026 earnings at ($0.19) EPS and FY2026 earnings at ($0.65) EPS.
Immix Biopharma Price Performance
IMMX stock traded up $0.18 during midday trading on Thursday, reaching $2.37. 185,785 shares of the company's stock traded hands, compared to its average volume of 155,177. The company has a market capitalization of $66.07 million, a P/E ratio of -2.79 and a beta of 0.31. Immix Biopharma has a fifty-two week low of $1.26 and a fifty-two week high of $3.00. The business has a 50-day moving average price of $1.91 and a two-hundred day moving average price of $1.95.
Immix Biopharma (NASDAQ:IMMX - Get Free Report) last announced its quarterly earnings results on Monday, March 24th. The company reported ($0.16) earnings per share for the quarter, beating analysts' consensus estimates of ($0.25) by $0.09.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Immix Biopharma stock. SBI Securities Co. Ltd. purchased a new stake in shares of Immix Biopharma, Inc. (NASDAQ:IMMX - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 17,500 shares of the company's stock, valued at approximately $38,000. SBI Securities Co. Ltd. owned approximately 0.06% of Immix Biopharma as of its most recent SEC filing. 11.26% of the stock is owned by hedge funds and other institutional investors.
Immix Biopharma Company Profile
(
Get Free Report)
Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.
Recommended Stories
Before you consider Immix Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immix Biopharma wasn't on the list.
While Immix Biopharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
